Chemotherapy Combination for Breast Cancer
Author Information
Author(s): Conte P F, Donati S, Gennari A, Guarneri V, Orlandini C, Rondini M, Roncella M, Marini L, Collecchi P, Viacava P, Naccarato A G, Degli Esposti R, Bonardi S, Bottini A, Saracchini S, Tumolo S, Gullo G, Santoro A, Crino L
Primary Institution: University of Modena and Reggio Emilia
Hypothesis
The study aims to assess the activity and tolerability of the gemcitabine, epirubicin, and taxol combination in patients with operable breast cancer.
Conclusion
The gemcitabine, epirubicin, and taxol regimen is active and well tolerated as primary chemotherapy for operable breast cancer.
Supporting Evidence
- The overall clinical response rate was 87.8%, with 26.8% complete responses.
- A pathological complete response was observed in six patients (14.6%).
- Grade 4 neutropenia was observed in 67.4% of the patients.
Takeaway
Doctors tested a combination of three medicines to help women with early breast cancer, and it worked well without too many side effects.
Methodology
Patients received gemcitabine, epirubicin, and taxol every 21 days for four cycles, and their responses were evaluated.
Limitations
The study had a limited sample size and did not document nodal status at study entry.
Participant Demographics
The median age of participants was 48 years, with the majority having stage II disease and positive hormone receptors.
Statistical Information
P-Value
P<0.05
Confidence Interval
95% CI 77.8–97.8
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website